Viral Inactivation Patents: Who Leads, Where the Gaps Are 2026
Viral inactivation patents: mapping who holds the claims and what is still open
Concentrated at the top. Five assignees hold 33.8% of all 770 records in scope, and ten hold 53.8% — most of the field's claim space sits with a small group. Filings peaked at 97 in 2018 and have declined since, falling from 71 in 2021 to 10 in 2024 (-86%). Treat 2025 and 2026 counts as incomplete — publication typically lags filing by about 18 months, so the most recent years understate actual filing activity rather than confirming a continued fall.
- 1TAKEDA PHARMA CO LTD100
- 2AMGEN INC57
- 3BAXTER INT INC35
- 4ALEXION PHARMACEUTICALS INC34
- 5NAJIT TECHNOLOGIES INC34
See the full viral inactivation methods analysis in Eureka
- The complete ranking, not just the top five
- Every IPC branch with its share of the corpus
- The most-cited records, and where claim space is still thin
Common questions on viral inactivation patents
Who holds the most patents on viral inactivation methods?
One assignee leads the ranking with 100 of the 770 records in scope, well ahead of the fifth-place holder at 34 and tenth place at 27. The top five assignees combined account for 33.8% of all records, and the top ten for 53.8%, showing a field where claim ownership is concentrated among a handful of established pharmaceutical and blood-product companies rather than spread evenly. Newer entrants mostly appear as single or few-filing entities in the long tail below that group.
Is viral inactivation patent filing activity growing or shrinking?
Filings peaked at 97 in 2018 and have declined since, falling from 71 in 2021 to just 10 in 2024, an 86% drop over that three-year span. Because patent publication typically lags actual filing by around 18 months, the 2025 and 2026 figures in any dataset are still incomplete and should not be read as confirming a continued decline on their own. Based on the complete years available, however, the trend through 2024 is clearly downward from the 2018 peak.
What technology areas dominate viral inactivation patent claims?
Medicinal preparations (IPC class A61K) appear in 45.3% of the 770 records in scope, followed by microorganism and genetic engineering claims (C12N) at 38.3%, peptide and protein chemistry (C07K) at 37.4%, and sterilising or disinfecting methods (A61L) at 35.8%. Because a single patent record can carry several IPC classes, these percentages add up to more than 100% and should each be read against the full 770-record total rather than against one another. Separation and filtration processes (B01D) are comparatively minor at 9.7%.
Disclaimer. This analysis is based on Patsnap Eureka data drawn from a limited snapshot of global patent records and is provided for general information and reference only. Patent data carries inherent limitations — recent filings are under-counted because of publication lag, counts may be on a record or family basis, classification and applicant-name data may contain errors or duplicates, and the underlying search query defines the scope shown — so the analysis may be incomplete or inaccurate and may not reflect the full technology landscape.
Nothing here is an exhaustive prior-art, novelty, freedom-to-operate or validity search, nor does it constitute legal, financial or professional advice, and it should not be relied upon as such. Verify independently and review with qualified patent and legal professionals before acting on it.
Method: Filing trend and technology composition. Derived from a Patsnap search on Viral Inactivation Methods covering 2015–2026, data cut-off 2026-07-31. Counts reflect published records only and shift as new filings publish. Every share divides by all records in scope. Data: Patsnap Eureka. See the full landscape report.